Results 1 to 10 of about 704 (128)

Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis [PDF]

PLoS ONE, 2014
Sutezolid (PNU-100480) is a linezolid analog with superior bactericidal activity against Mycobacterium tuberculosis in the hollow fiber, whole blood and mouse models.
Robert S Wallis, Andreas H Diacon
exaly   +13 more sources

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB [PDF]

Journal of Antimicrobial Chemotherapy
Funding: This study was conducted by the PanACEA consortium, funded by the EDCTP2 programme (grant number TRIA2015-1102) with support from the German Ministry for Education and Research (BMBF; 01KA1701); further funding was contributed by the German ...
Rob E Aarnoutse, Jodie Anne Schildkraut, Michael Hoelscher   +2 more
exaly   +14 more sources

In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China [PDF]

Infection and Drug Resistance, 2021
Xia Yu,* Fengmin Huo,* Fen Wang,* Shu’an Wen, Guanglu Jiang, Yi Xue, Lingling Dong, Liping Zhao, Rui Zhu, Hairong Huang National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing ...
Yu X, Huo F, Wang F, Wen S, Jiang G, Xue Y, Dong L, Zhao L, Zhu R, Huang H   +9 more
doaj   +6 more sources

To be or not to be exclusive: the sutezolid story [PDF]

The Lancet Global Health, 2016
Response from Johns Hopkins University Johns Hopkins University is deeply committed to providing access to essential medicines, and has been working for years to advance the goal of ensuring that promising therapies for tuberculosis reach the market in an expeditious and accessible way.
Christy Wyskiel
exaly   +12 more sources

Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China [PDF]

International Journal of Infectious Diseases, 2021
Background: The natural resistance of rapidly growing mycobacteria (RGM) to multiple antibiotics renders the treatment of the infections caused less successful.
Xiaopan Gao, Yuxia, Hairong Huang
exaly   +6 more sources

Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects [PDF]

Antimicrobial Agents and Chemotherapy, 2022
The primary objective of the study was to evaluate the safety and tolerability of single oral doses of sutezolid tablets administered under fasting conditions in healthy adult subjects. The secondary objective was to determine the pharmacokinetics (PK) of sutezolid and two metabolites, PNU-101603 and PNU-101244.
Paul Bruinenberg, Jerry R Nedelman
exaly   +5 more sources

Neuromyelitis optica causing vision loss during TB treatment with sutezolid: evidence of aberrant immunity following infection [PDF]

IJTLD Open
Contains fulltext : 319485.pdf (Publisher’s version ) (Open Access)
N.A. Glover, L. Paramo, S. Giangregorio, B. Sukwana, S.E. Koele, S. Charalambous, T. Ngwanto, S. Mashatole, D. Mudzengi, N. Heinrich, E.M. Svensson, F. Abdullah, G. Churchyard, R.S. Wallis   +13 more
doaj   +6 more sources

A Tandem Ring Closure and Nitrobenzene Reduction with Sulfide Provides an Improved Route to an Important Intermediate for the Anti-Tuberculosis Drug Candidate Sutezolid [PDF]

Organic Process Research and Development
Sutezolid is an in-development thiomorpholine derivative of the FDA-approved tuberculosis (TB) treatment linezolid. Current synthetic routes for preparing sutezolid start with thiomorpholine as a key structural building block; unfortunately, this material was identified as a major cost driver for the API, which will limit the potential uptake of this ...
Hanuman P Kalmode, Dinesh J Paymode, Sarah L Bliese Bs   +2 more
exaly   +6 more sources

New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? [PDF]

Pharmaceutics
Multidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity.
Andrew J Burke, Jin-Gun Cho, Jan-Willem C Alffenaar   +2 more
exaly   +4 more sources

Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis [PDF]

Pharmaceuticals
Mycobacterium tuberculosis infections continue to pose a significant global health challenge, particularly due to the rise of multidrug-resistant strains, random mycobacterial mutations, and the complications associated with short-term antibiotic ...
Ahmad Diab, Henry Dickerson, Othman Al Musaimi   +2 more
doaj   +5 more sources